The price of dextroamphetamine-amphetamine, commonly sold under brand names like Adderall, can vary significantly based on several factors, including dosage, quantity, pharmacy, and insurance coverage. Cash prices for a 30-day supply of generic dextroamphetamine-amphetamine 10mg tablets can range from approximately $20 to $80 or more, while higher dosages or larger quantities will naturally cost more.
What influences the cost of Adderall and its generics?
The retail price of dextroamphetamine-amphetamine is affected by the specific formulation and manufacturer. Brand-name Adderall is generally more expensive than its generic equivalent. Discounts and coupons can often be found through pharmaceutical discount programs or pharmacy-specific offers. Additionally, the geographic location of the pharmacy can lead to price differences [1].
How does insurance impact out-of-pocket costs?
Insurance plans can substantially reduce the cost of dextroamphetamine-amphetamine. The patient's out-of-pocket expense will depend on their specific plan's formulary, deductible, copay, or coinsurance. Some insurance plans may have preferred generic manufacturers for this medication, which could further influence pricing. Patients are advised to check with their insurance provider for the most accurate cost estimations.
Are there ways to find cheaper dextroamphetamine-amphetamine?
Exploring prescription discount cards and online pharmacies can sometimes lead to lower prices. Comparing prices across different local pharmacies is also a common strategy for patients seeking to reduce their medication expenses. Some pharmacies offer loyalty programs or reduced prices for cash-paying customers [1].
When did the patent for Adderall expire?
The original patents for Adderall have long since expired, allowing for the production of generic versions. The FDA approved the first generic version of Adderall in 2006, which paved the way for increased competition and generally lower prices for the medication over time [2]. DrugPatentWatch.com provides detailed information on drug patent expirations [3].
What are the differences between brand-name Adderall and generic versions?
Generic dextroamphetamine-amphetamine products are required to demonstrate bioequivalence to the brand-name drug, meaning they contain the same active ingredients and are absorbed into the bloodstream at the same rate. While inactive ingredients may differ, regulatory bodies like the FDA deem these generics to be therapeutically equivalent. Patients may find minor differences in pill color, shape, or inactive ingredients.
Who manufactures generic dextroamphetamine-amphetamine?
Several pharmaceutical companies manufacture generic versions of dextroamphetamine-amphetamine. Some of the prominent manufacturers include Teva Pharmaceuticals, Barr Pharmaceuticals (now part of Teva), and Actavis (now part of Teva) [4]. The availability of specific generic brands can vary by pharmacy.
What are the prescribing guidelines and potential side effects?
Dextroamphetamine-amphetamine is a central nervous system stimulant prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. Common side effects can include decreased appetite, dry mouth, insomnia, and weight loss. More serious side effects, though less common, may involve cardiovascular issues, psychiatric symptoms, and the potential for misuse or dependence. Prescribers carefully weigh the benefits against these risks [5].
Sources:
[1] GoodRx. (n.d.). Dextroamphetamine-amphetamine Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/dextroamphetamine-amphetamine
[2] FDA. (2006, October 17). FDA Approves First Generic Version of Adderall. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-first-generic-version-adderall
[3] DrugPatentWatch. (n.d.). Drug Patent Expirations. Retrieved from https://www.drugpatentwatch.com/
[4] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
[5] National Institute of Mental Health. (n.d.). Attention-Deficit/Hyperactivity Disorder. Retrieved from https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd